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Abstract
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased thrombotic and
cardiovascular risk, which are key contributors to patient morbidity and mortality. The Veterans Health Administration
(VHA) is the largest integrative health network in the United States. Available data concerning patients with PV in this
population are limited.
Methods: This retrospective observational study evaluated the characteristics, management, and outcomes of patients
with PV in the VHA Medical SAS® Dataset (October 1, 2005, to September 30, 2012). Inclusion criteria were≥ 2 claims
for PV (ie, PV diagnostic code was recorded) ≥30 days apart during the identification period, age ≥ 18 years, and
continuous health plan enrollment from ≥12 months before the index date until the end of follow-up. All data
were analyzed using descriptive statistics.
Results: The analysis included 7718 patients (median age, 64 years; male, 98%; white, 64%). The most common
comorbidities before the index date were hypertension (72%), dyslipidemia (54%), and diabetes (24%); 33% had a
history of smoking. During the follow-up period (median, 4.8 years), most patients did not receive treatment with
cytoreductive therapy, including phlebotomy (53%), or antiplatelet agents, such as aspirin (57%). The thrombotic
and cardiovascular event rates per 1000 patient-years were 60.5 and 83.8, respectively. Among patients who received
cytoreductive treatment, the thrombotic event rate was 48.9 per 1000 patient-years. The overall mortality rate was 51.2
per 1000 patient-years.
Conclusion: The notable rates of thrombotic and cardiovascular events observed in this analysis, even among patients
receiving cytoreductive treatment, highlight the important unmet clinical needs of patients with PV in the VHA.
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Background
Polycythemia vera (PV) is a myeloproliferative neoplasm
(MPN) [1] that affects > 140,000 patients in the United
States [2]. In the National Cancer Institute−sponsored
Surveillance, Epidemiology, and End Results cancer
registry, the incidence of PV per 100,000 persons in-
creased with advancing age (0.1 for < 34 years, 0.7 for
35–49 years, 2.4 for 50–74 years, and 5.3 for > 75 years)
and was higher for men (1.3 vs 0.8 for women) and
whites (1.1 vs 0.7 for African Americans and 0.8 for
other race groups) [3]. Analyses of PV patient popula-
tions have estimated that arterial and venous thrombotic
events occur at rates of 7 to 21 and 5 to 20 per 1000
person-years, respectively [4–7]. Thrombotic and cardio-
vascular events are among the leading causes of death in
patients with PV [8], contributing to lower overall sur-
vival compared with age- and sex-matched members of
the general population [9].
The treatment goals for patients with PV focus primar-
ily on preventing or managing thrombotic and bleeding
complications [10]. The European Collaboration on
Low-Dose Aspirin in Polycythemia Vera (ECLAP) study
demonstrated that treatment with low-dose aspirin was
associated with reduced risk of thrombotic events and
death from cardiovascular causes [11]. Results from the
Cytoreductive Therapy in Polycythemia Vera (CYTO-
PV) trial supported treatment with phlebotomy to
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maintain hematocrit levels < 45% and reduce the risk of
cardiovascular events and deaths resulting from throm-
botic or cardiovascular events [12]. In addition, some pa-
tients benefit from cytoreductive treatment with
hydroxyurea [13], interferon-α [14], or ruxolitinib [15,
16]. Ruxolitinib was approved by the US Food and Drug
Administration (FDA) in 2014 for patients with PV who
have had an inadequate response to or are intolerant of
hydroxyurea, and it remains the only pharmaceutical
agent approved by the FDA for the PV setting [17].
Real-world data on patient characteristics and clinical
management of patients with PV help inform the under-
standing of the population and identification of unmet
clinical needs. The Veterans Health Administration
(VHA), the largest integrated health-care system in the
United States, maintains patient records for US veterans
receiving care in Veterans Integrated Service Networks.
This is the first study to describe the demographics, clin-
ical characteristics, management, and thrombotic and




This retrospective, observational study analyzed longitu-
dinal data from the VHA Medical SAS® Dataset catalo-
gued between October 1, 2005, and September 30, 2012
(Fig. 1). The VHA data set included deidentified patient-
level data from 21 Veterans Integrated Service Networks
linking inpatient, outpatient, pharmacy, laboratory, en-
rollment, and vital sign databases.
Patients
Patients who had ≥2 claims (ie, diagnostic code was re-
corded) for PV (defined as International Classification of
Diseases, Ninth Edition, Clinical Modification [ICD-9-
CM] code 238.4) ≥30 days apart during the identification
period (January 1, 2007, to December 31, 2009) were
included in the analysis. Additional inclusion criteria
were age ≥ 18 years old on the index date (defined as the
date of each patient’s first claim with a PV diagnosis dur-
ing the identification period) and continuous health plan
enrollment with medical and pharmacy benefits from
≥12 months before the index date (ie, pre-index period)
until the end of follow-up. Patients were followed from
the index date until the date of death, date of disenroll-
ment, or end of the study period (September 30, 2012),
whichever occurred first.
Assessments and analyses
Patient demographics at index were reported. Assess-
ments of pre-index patient characteristics included co-
morbidities, mean Deyo-Charlson Comorbidity Index (a
weighted score [range, 1–6] of disease severity calculated
using 19 conditions) [18], mean Chronic Disease Score
(an aggregate comorbidity measure based on medication
use) [19], and patient histories of thrombotic and cardio-
vascular events.
Patient records were reviewed for PV treatments and
concomitant medications received; hematocrit level and
white blood cell (WBC) count measures; and throm-
botic, cardiovascular, and mortality events that occurred
between the index date and the end of the follow-up
period. Among patients with evaluable laboratory data,
the proportions of patients with elevated hematocrit and
WBC counts were recorded at the pre-index period and
annually during the follow-up period. Hematocrit levels
≥45% and WBC counts ≥11 × 109/L were considered
elevated. Thrombotic and cardiovascular events were
not mutually exclusive (acute myocardial infarction,
ischemic stroke, and transient ischemic attack spanned
both categories), and were identified by ICD-9-CM diag-
nosis codes recorded in patient claims (Additional file 1:
Table S1).
All data were analyzed using descriptive statistics.
Fig. 1 Study design. PV, polycythemia vera. *≥ 12 months. †Patients were followed up from the index date until the date of the earliest event:
death, disenrollment, or end of the study period. ‡The index date was defined as the date of each respective patient’s first claim with a PV diagnosis
during the identification period
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Results
Baseline patient demographic and clinical characteristics
In all, 7718 patients with PV were included in the
analysis. Most patients were ≥ 60 years of age (70.7%),
male (97.9%), and white (63.9%; Table 1). Before the
index date, hypertension (71.7%), dyslipidemia (54.2%),
and diabetes (24.0%) were the most common comorbidi-
ties. The mean (SD) Chronic Disease Score was 6.3 (4.2).
A notable proportion of patients experienced thrombotic
(arterial, 8.8%; venous, 4.5%) or cardiovascular (17.0%)
events within a year before the index date. Among
patients with available laboratory data, ≥1 elevated
hematocrit level or WBC count was reported in 90.2%
and 36.5% of patients, respectively, within a year before
the index date. One third (33.1%) of patients had a
history of smoking.
Laboratory values during follow-up
The median duration of follow-up was 4.8 years. Among
patients with available laboratory data, ≥1 elevated
hematocrit level was reported in 85.9% of patients dur-
ing the first year of follow-up and in 91.6% by the end of
follow-up (Table 2). The proportion of patients who ex-
perienced ≥1 elevated WBC count was 34.4% during the
first year of follow-up and 51.4% by the end of follow-
up. Many patients experienced ≥2 elevated hematocrit
levels (86.7%) or WBC counts (37.3%) during follow-up.
Cytoreductive therapy use during follow-up
During follow-up, only 23.2% of patients had documenta-
tion of any pharmacologic cytoreductive treatment
(Table 3). Among those who received cytoreductive ther-
apy (n = 1787), hydroxyurea was used most often (86.7%
[1550/1787]). Only 32.8% of all patients had a record of
treatment with phlebotomy, and more than half of all pa-
tients (53.0%) had no record of cytoreductive treatment or
phlebotomy. Overall, fewer than 1 in 10 patients (8.9%) re-
ceived both cytoreductive treatment and phlebotomy. The
most common concomitant medications were antihyper-
tensive agents and antilipid/anticholesterol agents, each
received by a majority of patients; anticoagulants were re-
ceived by 17.0% of patients (Table 3).
Thrombotic and cardiovascular events during follow-up
Thrombotic and cardiovascular events occurred in 22.9%
and 30.1% of patients, respectively (Table 4). The rate of
thrombotic events during follow-up was 60.5 per 1000
patient-years. Arterial thrombotic events were approxi-
mately twice as common as venous events; the most com-
mon arterial and venous thrombotic events were ischemic
stroke (10.7%) and deep vein thrombosis (6.9%), respect-
ively (Table 4). The rate of thrombotic events was 48.9 per
1000 patient-years among patients who received cytore-
ductive treatment before the event. Cardiovascular events
occurred at a rate of 83.8 per 1000 patient-years. On aver-
age, the first thrombotic and cardiovascular events oc-
curred 1.4 years after the index date. Overall, 1776 (23.0%)
patients died during follow-up, which was a mean 2.8 years
Table 1 Patient Demographics and Clinical Characteristics
Patients With
PV (N = 7718)
Age at index date,a y
Mean (SD) 65.9 (11.3)
Median (range) 64 (21–93)
Age, n (%)
18–45 y 256 (3.3)
46–59 y 2004 (26.0)










Deyo-Charlson Comorbidity Index, mean (SD) 1.4 (1.7)
Chronic Disease Score, mean (SD) 6.3 (4.2)







History of smoking,e n (%) 2551 (33.1)
Elevated, pre-index,a n/Nf (%)
Hematocrit level 5608/6214 (90.2)
WBC count 2365/6477 (36.5)
Thrombotic events,d pre-index,a n (%)
Arterial thrombosis 681 (8.8)
Venous thrombosis 349 (4.5)
Cardiovascular events pre-index,a n (%) 1315 (17.0)
ICD-9-CM International Classification of Diseases, Ninth Edition, Clinical Modification,
PV polycythemia vera, WBC white blood cell
aThe index date was defined as the date of each respective patient’s first claim
with a PV diagnosis during the identification period
bHawaiian or other Pacific Islander (0.8%), Alaska native or American Indian
(0.6%), Asian (0.4%)
cMissing (21.1%), declined to answer (3.1%), or unknown by patient (1.4%)
dNumber of patients with ≥1 event. Patients may be counted in > 1 subcategory
eSmoking status was determined through ICD-9-CM code 305.1, V15.82
fElevated defined as hematocrit level ≥ 45%, WBC count ≥11 × 109/L; N represents
patients with evaluable laboratory data
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after the index date. The mortality rate was 51.2 per 1000
patient-years (Table 4).
Discussion
In this analysis of 7718 patients diagnosed with PV in
the VHA population, there was a substantial burden of
thrombotic and cardiovascular events. During follow-up,
nearly a quarter of patients had a thrombotic event, and
almost one-third experienced a cardiovascular event.
The thrombotic event rate (60.5 per 1000 patient-years)
was higher than rates reported for cohorts of patients
with PV in the general population (14.3 to 38 per 1000
patient-years) [5–7], even among high-risk patients
(diagnosis before 2005, 40.1 per 1000 patient-years; after
2005, 29.3 per 1000 patient-years) [20].
There are several plausible contributors to the ele-
vated thrombotic event rate in the VHA population.
First, the VHA population may inherently have more
risk factors for thrombotic events. Patients had a not-
able comorbid disease burden at baseline, and the preva-
lence of traditional cardiovascular risk factors such as
hypertension, dyslipidemia, diabetes, and smoking [21]
was high. Although not measured in our analysis, the
prevalence of psychological comorbidities (eg, adjustment
disorder, anxiety, depression, posttraumatic stress dis-
order, substance use disorder) [22] and other psychosocial
issues (eg, homelessness) [23] are also elevated in the
VHA patient population, which may complicate manage-
ment of thrombotic and cardiovascular events. Finally, the
catchment area overseen by VHA providers may be larger
than the area covered by some traditional hematology
providers, which could confound travel logistics and
scheduling for some patients, thereby impeding some
standard practices (eg, frequent phlebotomy, coordination
of care, obtaining outside laboratory tests) [24].
Although the care provided during the follow-up
period may have been appropriate by the standards of the
time, current standard practice based on more recent evi-
dence may be associated with improved patient care. Of
interest, 3 in 4 patients had no documentation of any
pharmacologic cytoreductive treatment, and more than
half had no documentation of pharmacologic cytoreductive
treatment or phlebotomy. The low cytoreductive treatment
rate in this population may explain why 9 in 10 patients
had elevated hematocrit levels and 1 in 3 had elevated
WBC counts. These findings are important; the CYTO-PV
study indicated that elevated hematocrit and WBC counts
were associated with increased risk of PV-related clinical
complications [12, 25]. The cytoreductive treatment pat-
terns observed in our study may be related to the available
evidence at the time. For example, CYTO-PV study results
Table 2 Patients With Elevated Hematocrit Levels and WBC
Counts During the Follow-Up Period
Laboratory Value, n/N (%)a Patients With PV
≥1 elevated hematocrit levelb
12-month follow-up period 5350/6230 (85.9)
24-month follow-up period 6167/6974 (88.4)
36-month follow-up period 6397/7115 (89.9)
48-month follow-up period 6492/7140 (90.9)
Entire follow-up period 6544/7142 (91.6)
≥1 elevated WBC countc
12-month follow-up period 2163/6280 (34.4)
24-month follow-up period 2851/6966 (40.9)
36-month follow-up period 3239/7113 (45.5)
48-month follow-up period 3494/7136 (49.0)
Entire follow-up period 3671/7137 (51.4)
PV polycythemia vera, WBC white blood cell
aN represents patients with evaluable laboratory data
bDefined as hematocrit ≥45%
cDefined as WBC count ≥11 × 109/L
Table 3 PV Treatment Patterns and Concomitant Medications
During the Follow-Up Period
Treatment, n (%) Patients With
PV (N = 7718)
PV-related treatmenta










No cytoreductive treatment or phlebotomy 4088 (53.0)
Aspirind 1815 (23.5)
Antiplatelet agents, not including aspirin 1511 (19.6)
Common concomitant medications
Antihypertensive agents 6671 (86.4)
ACE inhibitors 4226 (54.8)
Antilipid/anticholesterol agents 4882 (63.3)
Antidiabetic agents 2163 (28.0)
Anticoagulants 1313 (17.0)
Inotropic agents 580 (7.5)
Antiarrhythmic agents 362 (4.7)
ACE angiotensin-converting enzyme, PV polycythemia vera
aRuxolitinib received approval from the US Food and Drug Administration for
patients with PV who have had an inadequate response to or are intolerant of
hydroxyurea after the end of the study period
bPatients receiving pharmacologic cytoreductive treatment may have also
received phlebotomy
cPatients receiving phlebotomy may have also received pharmacologic
cytoreductive treatment
dIncludes both prescribed and over-the-counter aspirin and may underrepresent
actual aspirin use
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demonstrating the clinical benefit of hematocrit mainten-
ance < 45% [12] and WBC counts < 11 × 109/L [25] were
not published until after the study period of this analysis.
However, some data concerning the clinical benefits of
cytoreductive therapy, in particular hydroxyurea, predated
the study period [13, 26]. It is interesting that few patients
had documented treatment with aspirin or other
antiplatelet therapy. This may be a consequence of
anticoagulant use or an artifact of low-dose aspirin being
available over the counter (ie, may not be reflected in the
medication dispensing forms). Findings from the ECLAP
study published in 2004 demonstrated that low-dose as-
pirin reduced the risk of cardiovascular events in patients
with PV [11]. Recent data suggest that patients with PV
and hypertension who are treated with angiotensin-
converting enzyme (ACE) inhibitors may require less
cytoreductive treatment to control hematocrit levels
compared with those who are treated with other antihyper-
tensive agents [27]. The current analysis found that the
majority of patients with PV received an ACE inhibitor
during follow-up, but usage rates were similar regardless of
cytoreductive treatment (data not shown). It may be im-
portant in future analyses to continue to report the associ-
ation between ACE inhibitor and cytoreductive medication
use on patient outcomes.
Of note, even among a subset of patients receiving
cytoreductive treatment, the thrombotic and cardiovascu-
lar risk remained high. Approximately 1 in 4 patients
treated with cytoreductive therapy experienced thrombotic
events during follow-up, and nearly 1 in 3 had cardiovas-
cular events. These data indicate an unmet clinical need in
patients treated with traditional options and may in part
explain why such a large proportion of patients were not
receiving cytoreductive treatment during follow-up.
Table 4 Thrombotic Events, Cardiovascular Events, and Deaths Occurring During the Follow-Up Period
Event Patients With








Among all patients with PV (N = 7718)
Thrombotic event 1771 (22.9) 1.4 29,276.2 60.5 57.7–63.4
Arterial 1275 (16.5) 1.5 30,874.3 41.3 39.1–43.6
Ischemic stroke 825 (10.7) 1.4 32,216.2 25.6 23.9–27.4
Transient ischemic attack 344 (4.5) 1.6 33,609.5 10.2 9.2–11.4
Acute myocardial infarction 224 (2.9) 2.3 34,167.1 6.6 5.8–7.5
Peripheral arterial thrombosis 109 (1.4) 2.0 34,364.7 3.2 2.6–3.8
Venous 678 (8.8) 1.4 32,621.4 20.8 19.3–22.4
Deep vein thrombosis 535 (6.9) 1.4 32,992.0 16.2 14.9–17.7
Pulmonary embolism 234 (3.0) 1.7 34,029.2 6.9 6.1–7.8
Superficial thrombophlebitis 42 (0.5) 1.9 34,529.8 1.2 0.9–1.7
Cardiovascular event 2325 (30.1) 1.4 27,750.5 83.8 80.4–87.3
Heart failure 1442 (18.7) 1.5 30,730.4 46.9 44.6–49.4
Ischemic stroke 825 (10.7) 1.4 32,216.2 25.6 23.9–27.4
Transient ischemic attack 344 (4.5) 1.6 33,609.5 10.2 9.2–11.4
Acute myocardial infarction 224 (2.9) 2.3 34,167.1 6.6 5.8–7.5
Unstable angina 185 (2.4) 2.3 34,193.5 5.4 4.7–6.3
Percutaneous coronary intervention 78 (1.0) 2.0 34,444.8 2.3 1.8–2.8
Coronary artery bypass graft 7 (0.1) 2.0 34,624.2 0.2 0.1–0.4
Mortality 1776 (23.0) 2.8 34,684.6 51.2 48.9–53.6
Among patients with PV receiving cytoreductive treatment (n = 1522)
Thrombotic event 295 (19.4) 2.2 6032.3 48.9 43.6–54.8
Among patients with PV not receiving cytoreductive treatment (n = 6196)
Thrombotic event 1476 (23.8) 1.2 23,243.8 63.5 60.3–66.8
PV polycythemia vera
aUp to the first respective event after diagnosis or end of the study period, whichever occurred first
bRate per 1000 patient-years was defined as 1000 × number of patients with first event/patient-years of total patients with PV
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Limitations of this analysis are primarily related to the
retrospective study design and reliance on the accuracy of
the database. The PV disease diagnosis, thrombotic
events, and other clinical conditions were identified using
ICD-9-CM codes, which are subject to potential miscod-
ing (eg, cases of secondary polycythemia may have been
logged as PV). Some PV-related treatments (eg, over-the-
counter aspirin, phlebotomy at blood centers) may not
have been recorded in the database and could have been
underrepresented in our analysis. Gaps between patient
visits could be long, during which time blood cell counts
and other clinical measures were unavailable; this may
have precluded an ability to observe long-term changes in
a consistent group of patients. Only 1 WBC count
≥11 × 109/L was required for patients to have an
elevated status, and it could have been caused by an
acute illness. However, previous data suggest that this
cutoff is important. In an analysis of the CYTO-PV
study, WBC count ≥11 × 109/L was associated with a 3.9-
fold increased risk of major thrombosis compared with
WBC count < 7 × 109/L (P = 0.02) [25]. Furthermore,
blood count analyses were incomplete because data were
not available for an informative analysis of platelet counts.
This VHA patient population was almost entirely male,
precluding an analysis of treatment and management
effects on thrombotic and cardiovascular events in female
patients. Finally, the exploratory nature of the analysis
precluded formal statistical analyses.
Conclusions
This retrospective analysis of the VHA population identi-
fied a substantial burden of thrombotic and cardiovascular
events among 7718 patients with PV managed between
2005 and 2012, before publication of the CYTO-PV re-
sults. Approximately 9 in 10 patients had elevated
hematocrit levels and 1 in 3 had elevated WBC counts,
which may increase the risk of PV-related clinical compli-
cations. The prevalence of additional cardiovascular risk
factors was high, placing this population at a greater risk
for thrombotic events. Surprisingly, many patients did not
have documented treatment with cytoreductive therapy or
phlebotomy. Collectively, these data suggest that some pa-
tients with PV in the VHA have unmet clinical needs that
may be ameliorated with the use of both traditional and
targeted cytoreductive treatment options. Recent clinical
practice guidelines from the National Comprehensive Can-
cer Network provide specific treatment recommendations
based on PV disease severity and response history [28].
Additional file
Additional file 1: Table S1. Thrombotic and Cardiovascular Event Codes.
This table presents the ICD-9-CM codes for thrombotic and cardiovascular
events employed in the study. (PDF 61 kb)
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